Protara Therapeutics Stock Performance
| TARA Stock | USD 7.00 0.08 1.13% |
On a scale of 0 to 100, Protara Therapeutics holds a performance score of 8. The company holds a Beta of 1.51, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Protara Therapeutics will likely underperform. Please check Protara Therapeutics' expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to make a quick decision on whether Protara Therapeutics' historical price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Protara Therapeutics are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unsteady basic indicators, Protara Therapeutics sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 1.14 | Five Day Return 16.07 | Year To Date Return 31.6 | Ten Year Return (98.06) | All Time Return (98.24) |
Last Split Factor 1:40 | Dividend Date 2020-01-10 | Last Split Date 2020-01-10 |
1 | Acquisition by Fabbio Patrick of 131000 shares of Protara Therapeutics at 1.91 subject to Rule 16b-3 | 11/07/2025 |
2 | Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphat... | 11/18/2025 |
3 | Protara Therapeutics starts 75M stock and pre-funded warrant sale - Stock Titan | 12/04/2025 |
4 | Protara Announces Closing of 75 Million Public Offering | 12/08/2025 |
5 | Why Protara Therapeutics Inc. stock could outperform in 2025 - Portfolio Performance Report High Accuracy Investment Signals - | 12/19/2025 |
6 | Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations | 01/05/2026 |
7 | XRP Retrace Is Only Temporary, What Happens Once the Uptrend Resumes | 01/08/2026 |
8 | TARA Media, SWYM.ai Bring AI-Powered Supply Shaping to Media Buying Platform | 01/15/2026 |
9 | Disposition of 2132 shares by Hannah Fry of Protara Therapeutics at 5.6 subject to Rule 16b-3 | 01/20/2026 |
10 | Acquisition by Hannah Fry of 9500 shares of Protara Therapeutics subject to Rule 16b-3 | 01/21/2026 |
11 | Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Canc... | 01/22/2026 |
12 | Disposition of 3724 shares by Zummo Jacqueline of Protara Therapeutics at 6.67 subject to Rule 16b-3 | 01/26/2026 |
13 | BYOMA ANNOUNCES NEW GLOBAL PRESIDENT AND CHIEF BRAND OFFICER | 01/27/2026 |
| Begin Period Cash Flow | 40.3 M | |
| Total Cashflows From Investing Activities | 19.2 M |
Protara Therapeutics Relative Risk vs. Return Landscape
If you would invest 512.00 in Protara Therapeutics on November 3, 2025 and sell it today you would earn a total of 188.00 from holding Protara Therapeutics or generate 36.72% return on investment over 90 days. Protara Therapeutics is currently generating 0.6967% in daily expected returns and assumes 6.2942% risk (volatility on return distribution) over the 90 days horizon. In different words, 56% of stocks are less volatile than Protara, and 86% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Protara Therapeutics Target Price Odds to finish over Current Price
The tendency of Protara Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 7.00 | 90 days | 7.00 | about 5.93 |
Based on a normal probability distribution, the odds of Protara Therapeutics to move above the current price in 90 days from now is about 5.93 (This Protara Therapeutics probability density function shows the probability of Protara Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.51 . This usually implies as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Protara Therapeutics will likely underperform. Additionally Protara Therapeutics has an alpha of 0.5982, implying that it can generate a 0.6 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Protara Therapeutics Price Density |
| Price |
Predictive Modules for Protara Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Protara Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Protara Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Protara Therapeutics is not an exception. The market had few large corrections towards the Protara Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Protara Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Protara Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.60 | |
β | Beta against Dow Jones | 1.51 | |
σ | Overall volatility | 0.82 | |
Ir | Information ratio | 0.10 |
Protara Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Protara Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Protara Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Protara Therapeutics is way too risky over 90 days horizon | |
| Protara Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (44.6 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Protara Therapeutics currently holds about 98.46 M in cash with (35.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.74, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Protara Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from simplywall.st: Were Not Very Worried About Microbot Medicals Cash Burn Rate |
Protara Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Protara Stock often depends not only on the future outlook of the current and potential Protara Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Protara Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 20.6 M | |
| Cash And Short Term Investments | 170.3 M |
Protara Therapeutics Fundamentals Growth
Protara Stock prices reflect investors' perceptions of the future prospects and financial health of Protara Therapeutics, and Protara Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Protara Stock performance.
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.31 | ||||
| Current Valuation | 246.1 M | ||||
| Shares Outstanding | 53.59 M | ||||
| Price To Book | 2.84 X | ||||
| EBITDA | (48.82 M) | ||||
| Net Income | (44.6 M) | ||||
| Cash And Equivalents | 98.46 M | ||||
| Cash Per Share | 8.74 X | ||||
| Total Debt | 4.48 M | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 28.94 X | ||||
| Book Value Per Share | 3.43 X | ||||
| Cash Flow From Operations | (35.81 M) | ||||
| Earnings Per Share | (1.41) X | ||||
| Market Capitalization | 379.4 M | ||||
| Total Asset | 181.45 M | ||||
| Retained Earnings | (244.98 M) | ||||
| Working Capital | 161.19 M | ||||
About Protara Therapeutics Performance
By analyzing Protara Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Protara Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Protara Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Protara Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.23) | (0.24) | |
| Return On Capital Employed | (0.33) | (0.35) | |
| Return On Assets | (0.22) | (0.23) | |
| Return On Equity | (0.31) | (0.32) |
Things to note about Protara Therapeutics performance evaluation
Checking the ongoing alerts about Protara Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Protara Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Protara Therapeutics is way too risky over 90 days horizon | |
| Protara Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (44.6 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Protara Therapeutics currently holds about 98.46 M in cash with (35.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.74, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Protara Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from simplywall.st: Were Not Very Worried About Microbot Medicals Cash Burn Rate |
- Analyzing Protara Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Protara Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Protara Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Protara Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Protara Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Protara Therapeutics' stock. These opinions can provide insight into Protara Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Protara Stock analysis
When running Protara Therapeutics' price analysis, check to measure Protara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protara Therapeutics is operating at the current time. Most of Protara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protara Therapeutics' price. Additionally, you may evaluate how the addition of Protara Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |